The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins

Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.

Completed

Looking for future studies?

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

University of Vermont

Burlington, Vermont, 05401, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

women routinely taking tamoxifen or aromatase inhibitor therapy as prescribed by their oncologist

Exclusion criteria

Use of heparin, warfarin

Treatment and study plan

Primary outcomes

Angiogenic Protein levels

Time frame: following 6 months of therapy

Sponsors and collaborators

Lead sponsor

University of Vermont

Other

Collaborators

American Cancer Society, Inc.

Registry information

Official study title

Platelet Modulation in the Control of Angiogenesis: The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Activation and Angiogenic Proteins

Important dates

Study start: 2009
Primary completion: 2018
Study completion: 2018
First posted: Apr 25, 2011
Registry last updated: Sep 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed